Transcription of Public Assessment Report Repeat-Use Mutual …
{{id}} {{{paragraph}}}
Example: tourism industry
Public Assessment Report Repeat-Use Mutual …
PAR SolarazeTM 3% Gel UK/H/0226/001/E022. Public Assessment Report Repeat-Use Mutual recognition Procedure SolarazeTM 3% Gel UK/H/0226/002/E02. UK licence no: PL 16973/0012. Almirall, 1. PAR SolarazeTM 3% Gel UK/H/0226/001/E022. LAY SUMMARY. This Repeat-Use Mutual recognition Procedure (UK/H/0226/001/E02) granted a Marketing Authorisation to Almirall SA for the medicinal product Solaraze 3% Gel (PL 16973/0012) in Greece, Spain and Poland; the procedure concluded positively on 18th November 2010. A. national licence for Solaraze 3% Gel was initially granted in the UK on 25th July 1997. Solaraze is a non-steroidal anti-inflammatory gel that is applied to the skin.
PAR SolarazeTM 3% Gel UK/H/0226/001/E022 1 Public Assessment Report Repeat-Use Mutual Recognition Procedure SolarazeTM 3% Gel UK/H/0226/002/E02 UK licence no: PL 16973/0012 Almirall, S.A
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
APO-Citalopram, Functional, Plant flavonoids as angiotensin converting enzyme, Guidelines for psychosocially assisted, Guidelines for psychosocially assisted pharmacological treatment, Excipient interaction and its importance, Health Homes, Connecticut, Advanced Therapy Medicinal Products ATMPs, Overview of preparation and